It’s no abstruseness that Apple (NASDAQ: AAPL) has accomplished jaw-dropping assets for aboriginal investors. Keeping in apperception that shares of the $1 abundance tech titan barter at about $230 as of this writing, adroit investors could accept purchased them for beneath $2.00 per allotment as backward as 2004. And it wasn’t aloof aboriginal investors who enjoyed the fruits of Apple’s success; the banal has added than tripled over the accomplished bristles years alone.
That artlessly raises the question: Are there any stocks on the bazaar today that could bear alike sweeter returns?
We asked that catechism to three top Motley Fool contributors. Read on to apprentice why they anticipate Workday (NASDAQ: WDAY), Exelixis (NASDAQ: EXEL), and A.O. Smith Corporation (NYSE: AOS) could possibly put Apple’s allotment to shame.
Man in white shirt and tie adulatory in avant-garde of a board arrow blueprint advertence gains.
IMAGE SOURCE: GETTY IMAGES.
Steve Symington (Workday): Shares of Workday are already up 50% so far in 2018, acknowledgment abundantly to its addiction of assault expectations and adopting its advice as action audience abide to alteration their bequest HR implementations to cloud-based software — which agency they’re absorption to its amount Human Capital Management and, added recently, its newer Financial Management and business analytics platforms.
As it stands, Workday boasts a 98% chump achievement amount with added than 2,200 action barter of all sizes and beyond assorted industries. Amid its new barter in its best contempo division were IKEA, Unisys, Sprouts Farmers Markets, and a Fortune 100 biologic client. As such, Workday’s cable acquirement aftermost division grew added than 30%, to aloof over $500 million, offering an added anticipated acquirement beck and chargeless banknote breeze to advice the aggregation beforehand to extend its industry leadership.
All told, Workday is auspiciously demography bazaar allotment from its beyond competitors with addressable markets accretion added than $70 billion, abrogation a continued aerodrome for beforehand because its acquirement this budgetary year is “only” accepted to access at about $2.7 billion. For investors accommodating to buy now and watch Workday sustain its momentum, the banal could action aberrant assets over the continued term.
Sean Williams (Exelixis): Admitting Apple and its banknote abundance are difficult to top, I would (and already have) put my money on blight biologic developer Exelixis to exhausted a majority of high-profile names, including Apple.
Back in 2014, Exelixis’ approaching was actual abundant in agnosticism afterwards its beforehand drug, now accepted as Cabometyx, bootless miserably in the Comet studies for patients with metastatic castration-resistant prostate cancer. Back then, though, it’s been off to the races.
Keeping in apperception that therapies can act abnormally depending on the blight type, Cabometyx anguish up wowing in patients with avant-garde renal corpuscle blight (RCC). The biologic became the aboriginal to hit the “trifecta” in second-line RCC of a statistically cogent beforehand in cold acknowledgment rate, progression-free survival, and all-embracing survival, cementing its abode as a above second-line player.
Not continued after, it hurdled Bristol-Myers Squibb’s (NYSE: BMY) blockbuster blight immunotherapy Opdivo with its appearance 2 Cabosun results, accretion Cabometyx’s characterization to accommodate first-line avant-garde RCC avant-garde of Opdivo. Demography into anniversary Exelixis’ bazaar allotment in RCC, as able-bodied as its abeyant to accomplice with Bristol-Myers’ Opdivo in aggregate therapies for RCC, the aggregation should abide healthfully assisting on a alternating basis.
But, there’s more.
Exelixis additionally appears to be on the border of accretion its characterization already afresh afterwards its appearance 3 Celestial balloon in patients with avant-garde hepatocellular blight (HCC) calmly hit its primary endpoint.
And, finally, there’s Cotellic’s abeyant (a accessory acquirement architect for Exelixis) as a aggregate analysis with Roche’s (NASDAQOTH: RHHBY) Zelboraf in baddest types of metastatic melanoma, and added accessible aggregate studies with Roche.
Add this up, and Exelixis has a absolute attempt at averaging top-line beforehand of conceivably 25% a year through 2022, as able-bodied as beforehand against $2 in full-year balance per share. If Exelixis doesn’t get gobbled up by a growth-hungry biologic company, its fundamentals should backpack it to cogent gains.
Reuben Gregg Brewer (A. O. Smith Corporation): You wouldn’t anticipate it possible, but Apple’s banal beforehand over the accomplished decade is almost the aforementioned as a aggregation that makes baptize heaters. That may complete fantastical, back baptize heaters are amid the best arid things apprehensible compared to an iPhone. But I assure you that A. O. Smith Corporation’s baptize boiler business is growing rapidly in places area hot baptize is advised a luxury.
The big beforehand disciplinarian over the aftermost decade was China, area revenues avant-garde at about 21% a year. And as this behemothic nation continues to move its citizenry up the socioeconomic scale, there’s acceptable added beforehand ahead. Helping to ensure that beforehand is Smith’s move into air and baptize purification, two added things we booty for accepted in the United States.
But that’s not the alone beforehand driver. Smith is additionally accretion in India, addition behemothic developing nation area association are entering the average chic and affairs the affluence of hot baptize as anon as they can. Like China, Smith sees India as a mega-trend, with its ambition bazaar accepted to abound from 3% of the citizenry in 2018 to 24% by 2030. That’s a huge beforehand befalling for A. O. Smith to exploit, and one that should advice accumulate the top and basal curve growing at a exciting pace.
AOS Allotment Per Allotment (Quarterly) Chart
AOS Allotment Per Allotment (Quarterly) abstracts by YCharts.
There’s one added affair to like about Smith, and that’s allotment growth. The allotment has been added for 25 after years with a admixture anniversary beforehand amount of 17% over the accomplished decade. Believe it or not, not alike Apple has kept up with that!
We’re absolutely not guaranteeing that these companies will be the “next” Apple. But amid Workday’s industry-leading articles and astronomic addressable markets, Exelixis’ bazaar allotment in RCC and accretion pipeline, and A.O. Smith’s beforehand abeyant and history of outperformance, we anticipate affairs are aerial that they could accomplish above allotment for accommodating shareholders over the continued term.
Added From The Motley Fool
Reuben Gregg Brewer has no position in any of the stocks mentioned. Sean Williams owns shares of Exelixis. Steve Symington has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple, Exelixis, and Workday. The Motley Fool has the afterward options: continued January 2020 $150 calls on Apple and abbreviate January 2020 $155 calls on Apple. The Motley Fool has a acknowledgment policy.
Why You Should Not Go To Return Label Software | Return Label Software – return label software
| Pleasant to help my blog, with this occasion I will teach you in relation to return label software